Lab Meeting 50 highlighted the impact and relationship between COVID-19 and mental health. First, Dr. Murali Doraiswamy of the Duke University School of Medicine facilitated a Q&A with Drs. Joshua Gordon, Director of the National Institute of Mental Health (NIMH), Dr. Susan Borja, also of NIMH, and Dr. Patrizia Cavazzoni of the US Food and Drug Administration’s (FDA) Center for Drug Evaluation & Research (CDER). Next, we heard from Dr. Scott Kollins of Holmusk about the challenges and opportunities of utilizing Real World Data (RWD) for understanding COVID’s impact on mental health. The third presentation by Reyna Taylor of the National Council for Mental Wellbeing introduced her organization’s efforts to enhance the capacity, coordination, and quality of community-based mental health care to meet increased demand for these services. Finally, Dr. Amar Bhat of the Reagan Udall Foundation for the FDA presented the data visualization of the week which highlights the demand for information on how to maintain mental well-being throughout the COVID-19 pandemic.
Full March 17 Lab Summary